

Lantheus Holdings, Inc.  
Form 8-K  
March 25, 2019

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): March 19, 2019**

**LANTHEUS HOLDINGS, INC.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**

**of incorporation)**

**331 Treble Cove Road, North Billerica, MA**

**001-36569**  
**(Commission**

**File Number)**

**35-2318913**  
**(IRS Employer**

**Identification No.)**

**01862**

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code: (978) 671-8001

**Not Applicable**

**(Former name or former address, if changed since last report.)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On March 19, 2019, Cesare Orlandi, M.D., the Chief Medical Officer of Lantheus Holdings, Inc. (the *Company* ), informed the Company of his intention to retire, effective September 2, 2019.

A copy of the Company's press release announcing Dr. Orlandi's retirement is attached hereto as Exhibit 99.1.

**Item 8.01. Other Events.**

On March 25, 2019, the Company announced its promotion of John Bolla from Senior Vice President, Technical Operations, to Chief Operations Officer of the Company, effective immediately.

A copy of the Company's press release announcing Mr. Bolla's promotion is attached hereto as Exhibit 99.1.

**Item 9.01. Financial Statements and Exhibits.**

**(d) Exhibits**

**Exhibit  
No.**

**Description**

99.1	<u>Press release of Lantheus Holdings, Inc. dated March 25, 2019, entitled <i>Lantheus Announces Upcoming Retirement of Chief Medical Officer in September 2019 and Promotion of Senior Vice President, Technical Operations to Chief Operations Officer</i></u>
------	--

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**LANTHEUS HOLDINGS, INC.**

By: /S/ Michael P. Duffy  
Name: Michael P. Duffy  
Title: General Counsel, Senior Vice  
President, Law and Public Policy, and  
Secretary

Date: March 25, 2019

**EXHIBIT INDEX**

**Exhibit  
No.**

**Description**

99.1 Press release of Lantheus Holdings, Inc. dated March 25, 2019, entitled Lantheus Announces Upcoming Retirement of Chief Medical Officer in September 2019 and Promotion of Senior Vice President, Technical Operations to Chief Operations Officer